Workflow
ImmunityBio(IBRX) - 2019 Q2 - Quarterly Report
ImmunityBioImmunityBio(US:IBRX)2019-08-06 20:07

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ to _____ Commission file number: 001-37507 NANTKWEST, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 43-1979754 (State or other jur ...